Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Star-tor - Registry For The Evaluation Of The Safety, Tolerability And Efficacy Of Temsirolimus (Torisel), Sunitinib (Sutent), And Axitnib (Inlyta) For The Treatment Of Subjects With Advanced Renal Cell Carcinoma (Mrcc), Mantle Cell Lymphoma (Mcl), And Gastro-intestinal Stroma Tumor (Gist).

Trial Profile

Star-tor - Registry For The Evaluation Of The Safety, Tolerability And Efficacy Of Temsirolimus (Torisel), Sunitinib (Sutent), And Axitnib (Inlyta) For The Treatment Of Subjects With Advanced Renal Cell Carcinoma (Mrcc), Mantle Cell Lymphoma (Mcl), And Gastro-intestinal Stroma Tumor (Gist).

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Nov 2018

At a glance

  • Drugs Axitinib (Primary) ; Sunitinib (Primary) ; Temsirolimus (Primary)
  • Indications Gastrointestinal stromal tumours; Mantle-cell lymphoma; Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms STAR-TOR
  • Sponsors Pfizer; Wyeth
  • Most Recent Events

    • 01 Nov 2018 Results assessing the efficacy and safety of sunitinib treatment modification in 1L treatment of mRCC (n=297), published in the Anticancer Research
    • 10 Feb 2018 Results (n=297) assessing if treatment dose modifications results in improved outcomes in patients receiving Sunitinib as first line presented at the 2018 Genitourinary Cancers Symposium
    • 08 Jan 2018 Planned End Date changed from 1 Dec 2019 to 1 Dec 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top